Cerecor to Host R&D Day in New York City on March 1, 2016

Cerecor to Host R&D Day in New York City on March 1, 2016

Download as PDF

Presentations to highlight unmet needs and emerging treatment options in depression and substance use therapy

BALTIMORE-- Cerecor Inc. (NASDAQ:CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it will host its first Research & Development Day in New York City on March 1, 2016, starting at 8:30 a.m. EST. Invited experts will discuss the current therapy landscape as well as novel approaches for treatment of depression and substance use.

Invited speakers include:

  • Bill A. Carlezon Jr., Ph.D., Chief, Division of Basic Neuroscience, McLean Hospital, Director, Behavioral Genetics Laboratory, McLean Hospital, Professor of Psychiatry, Harvard Medical School
  • Ginger Johnson, Ph.D., Vice President, Defined Health
  • Sanjay J. Mathews, M.D., Marjorie Bintliff Johnson and Raleigh White Johnson Jr. Chair for Research in Psychiatry, Baylor College of Medicine, Associate Professor of Psychiatry and Behavioral Sciences, Baylor College of Medicine

Advance event registration is required and attendance is limited to members of the professional investment community. To register or to learn more about the event, contact Joe Rayne at jrayne@macbiocom.com or (781) 235-3060.

Webcast

A live webcast and subsequent replay of the event may be accessed under the “Investors & Media” section of the company’s website at www.cerecor.com.

About Cerecor

Cerecor is a biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases. We are committed to the development of drugs that improve lives of patients by applying our extensive knowledge and experience in central nervous system disorders. Cerecor is currently pursuing the development of two clinical Phase II-stage product candidates: CERC-301: An oral, NR2B specific, NMDA receptor antagonist targeting the adjunctive treatment of patients with MDD who are failing to achieve adequate response, and CERC-501: A potent and selective kappa opioid receptor (KOR) antagonist targeting the adjunctive treatment of MDD and substance use disorders. In addition, Cerecor is conducting preclinical testing of CERC-406, a brain penetrant COMT inhibitor with potential procognitive activity. For more information about the Company and its products, please visit: www.cerecor.com or contact Mariam E. Morris, Chief Financial Officer, at (443) 304-8002.

MacDougall Biomedical Communications
Doug MacDougall or Joe Rayne, 781-235-3060
ir@cerecor.com

Source: Cerecor Inc.

Released February 22, 2016